Takara Bio subsidiary to build manufacturing facilities for antibodies and immunotherapy in Beijing

The GMP plant will be built by Takara Bio’s Chinese subsidiary TakaraMed and produce antibodies such as anti-CD3 monoclonal antibodies and vectors. The investment will be about 150 million yen, and the plant will be completed in July, 2013.

Takara Bio press release, Nov. 5, 2012

Takara Bio subsidiary to build manufacturing facilities for antibodies and immunotherapy in Beijing
Scroll to top